Literature DB >> 23510990

Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study.

Sophie C Flohil1, Robert J T van der Leest, Emmilia A Dowlatshahi, Albert Hofman, Esther de Vries, Tamar Nijsten.   

Abstract

Limited data are available on the prevalence and risk factors of actinic keratoses (AKs). Within the Rotterdam Study, full-body skin examinations were performed among participants aged 45 years or older to estimate the age- and sex-standardized prevalence of AK and its associated risk factors. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for associations between risk factors and the presence of 1-3, 4-9, and ≥ 10 AKs. Of the 2,061 inspected cohort members (mean age 72 years), 21% had 1-3, 9% had 4-9, and 8% had ≥ 10 AKs. AK prevalence was 49% (95% CI: 46-52%) for men and 28% (26-31%) for women. Male gender, older age, light pigmentation status, severe baldness, skin wrinkling, and high tendency for sunburn were significantly associated with extensive actinic damage (≥ 10 AKs) in the multivariate analyses. Especially bald males were at an increased risk of severe actinic skin damage (adjusted OR=7.0 (3.8-13.1)). The prevalence of AK is very high, especially among elderly bald males. The prevention and management of AK is a true challenge for patients, physicians, and health-care policymakers.

Entities:  

Mesh:

Year:  2013        PMID: 23510990     DOI: 10.1038/jid.2013.134

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  39 in total

1.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

Review 2.  Unravelling the human genome-phenome relationship using phenome-wide association studies.

Authors:  William S Bush; Matthew T Oetjens; Dana C Crawford
Journal:  Nat Rev Genet       Date:  2016-02-15       Impact factor: 53.242

3.  The Rotterdam Study: 2014 objectives and design update.

Authors:  Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2013-11-21       Impact factor: 8.082

4.  The phenotypic legacy of admixture between modern humans and Neandertals.

Authors:  Corinne N Simonti; Benjamin Vernot; Lisa Bastarache; Erwin Bottinger; David S Carrell; Rex L Chisholm; David R Crosslin; Scott J Hebbring; Gail P Jarvik; Iftikhar J Kullo; Rongling Li; Jyotishman Pathak; Marylyn D Ritchie; Dan M Roden; Shefali S Verma; Gerard Tromp; Jeffrey D Prato; William S Bush; Joshua M Akey; Joshua C Denny; John A Capra
Journal:  Science       Date:  2016-02-12       Impact factor: 47.728

5.  The Rotterdam Study: 2018 update on objectives, design and main results.

Authors:  M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman
Journal:  Eur J Epidemiol       Date:  2017-10-24       Impact factor: 8.082

Review 6.  Environmental effects of stratospheric ozone depletion, UV radiation and interactions with climate change: UNEP Environmental Effects Assessment Panel, update 2019.

Authors:  G H Bernhard; R E Neale; P W Barnes; P J Neale; R G Zepp; S R Wilson; A L Andrady; A F Bais; R L McKenzie; P J Aucamp; P J Young; J B Liley; R M Lucas; S Yazar; L E Rhodes; S N Byrne; L M Hollestein; C M Olsen; A R Young; T M Robson; J F Bornman; M A K Jansen; S A Robinson; C L Ballaré; C E Williamson; K C Rose; A T Banaszak; D -P Häder; S Hylander; S -Å Wängberg; A T Austin; W -C Hou; N D Paul; S Madronich; B Sulzberger; K R Solomon; H Li; T Schikowski; J Longstreth; K K Pandey; A M Heikkilä; C C White
Journal:  Photochem Photobiol Sci       Date:  2020-05-20       Impact factor: 3.982

7.  Variation in the Cost of Managing Actinic Keratosis.

Authors:  Joslyn S Kirby; Tanner Gregory; Guodong Liu; Douglas L Leslie; Jeffrey J Miller
Journal:  JAMA Dermatol       Date:  2017-04-01       Impact factor: 10.282

8.  Use and Cost of Actinic Keratosis Destruction in the Medicare Part B Fee-for-Service Population, 2007 to 2015.

Authors:  Howa Yeung; Marissa L Baranowski; Robert A Swerlick; Suephy C Chen; Jennifer Hemingway; Danny R Hughes; Richard Duszak
Journal:  JAMA Dermatol       Date:  2018-11-01       Impact factor: 10.282

Review 9.  Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update.

Authors:  Spencer M Vale; Dane Hill; Steven R Feldman
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

10.  Validity and Reliability of the Dutch Adaptation of the Actinic Keratosis Quality of Life Questionnaire (AKQoL).

Authors:  Kelly Vis; Rick Waalboer-Spuij; Dyon G C T M Snels; Loes M Hollestein
Journal:  Dermatology       Date:  2018-06-15       Impact factor: 5.366

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.